Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.
Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.